Promising results with cancer-fighting virus

May 22, 2008

Jennerex Biotherapeutics, a startup company based on the research of Dr. John Bell at the Ottawa Hospital Research Institute (OHRI) and Dr. David Kirn in San Francisco, has published promising results of a clinical trial with a cancer-fighting virus. The Phase I trial was published online in Lancet Oncology on May 19, 2008. Fourteen terminal cancer patients were treated and half survived more than eight months (life expectancy was three to four months).

The trial was conducted in Korea, in partnership with Green Cross Corporation. Further clinical trials will be conducted in Ottawa and other Canadian cities as soon as Health Canada approval is obtained.

Dr. Bell is the Chief Scientific Officer for Jennerex and also a Senior Scientist in the Cancer Therapeutics Program at OHRI (the research arm of The Ottawa Hospital) and a Professor of Medicine at the University of Ottawa.

For more information, see: